MBNP
MCID: MMB011
MIFTS: 50

Membranous Nephropathy (MBNP)

Categories: Nephrological diseases, Rare diseases

Aliases & Classifications for Membranous Nephropathy

MalaCards integrated aliases for Membranous Nephropathy:

Name: Membranous Nephropathy 56 12 52 29 15
Membranous Glomerulonephritis 12 52 15 17 71
Membranous Nephropathy, Susceptibility to 56 13
Idiopathic Membranous Glomerulonephritis 58 71
Idiopathic Membranous Nephropathy 52 54
Glomerulonephritis, Membranous 52 43
Primary Membranous Glomerulonephritis 58
Extramembranous Glomerulonephritis 52
Primary Membranous Nephropathy 58
Nephropathy Membranous 54
Membranous Gn 52
Mbnp 56
Mgn 52

Classifications:

Orphanet: 58  
Rare renal diseases


External Ids:

Disease Ontology 12 DOID:10976
OMIM 56 614692
MeSH 43 D015433
NCIt 49 C34645
SNOMED-CT 67 77182004
ICD10 32 N03.2
ICD10 via Orphanet 33 N04.2
UMLS via Orphanet 72 C0086445
Orphanet 58 ORPHA97560
UMLS 71 C0017665 C0086445

Summaries for Membranous Nephropathy

OMIM : 56 Membranous nephropathy, a major cause of the nephrotic syndrome in adults, is characterized by the presence of glomerular deposits that typically contain immunoglobulin and complement components. Two major antigens, both of which are membrane glycoproteins, have been identified in human membranous nephropathy. Neutral endopeptidase (MME; 120520) is the alloantigen involved in membranous nephropathy in neonates whose mothers have a deficiency of this enzyme. The second is the M-type phospholipase A2 receptor (PLA2R1; 604939), the first antigen identified in adults with idiopathic membranous nephropathy, which is generally considered to be an autoimmune disease. In addition, autoantibodies against aldose reductase (AKR1B1; 103880), mitochondrial superoxide dismutase-2 (SOD2; 147460), and THSD7A (612249) have been found in serum and glomeruli from patients with idiopathic membranous nephropathy. Familial occurrence has been noted by Short et al. (1984) and Bockenhauer et al. (2008) (summary by Stanescu et al., 2011 and Tomas et al., 2014). (614692)

MalaCards based summary : Membranous Nephropathy, also known as membranous glomerulonephritis, is related to end stage renal failure and nephrotic syndrome. An important gene associated with Membranous Nephropathy is MBNP (?Membranous Nephropathy, Susceptibility To), and among its related pathways/superpathways are Primary Focal Segmental Glomerulosclerosis FSGS and Nephrin/Neph1 signaling in the kidney podocyte. The drugs Tacrolimus and Mycophenolic acid have been mentioned in the context of this disorder. Affiliated tissues include kidney, t cells and b cells, and related phenotypes are Reduced mammosphere formation and homeostasis/metabolism

NIH Rare Diseases : 52 Membranous nephropathy is a kidney disease characterized by inflammation of the structures inside the kidney that help filter wastes and fluids. When the glomerular basement membrane becomes thickened, it does not work normally, allowing large amounts of protein to be lost in the urine. Symptoms develop gradually and may include swelling , fatigue, weight gain, and high blood pressure . In many cases, the underlying cause of membranous nephropathy is not known. Some cases are associated with other conditions (lupus ), infections (hepatitis B and C), cancer or as a side effect of certain medications. The goal of treatment is to reduce symptoms and slow the progression of the disease.

Wikipedia : 74 Membranous glomerulonephritis (MGN) is a slowly progressive disease of the kidney affecting mostly... more...

Related Diseases for Membranous Nephropathy

Diseases in the Membranous Nephropathy family:

Congenital Membranous Nephropathy Due to Fetomaternal Anti-Neutral Endopeptidase Alloimmunization

Diseases related to Membranous Nephropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 587, show less)
# Related Disease Score Top Affiliating Genes
1 end stage renal failure 31.6 NPHS2 NPHS1 ALB ACE
2 nephrotic syndrome 31.5 TRPC6 NPHS2 NPHS1 CD2AP ALB ACE
3 idiopathic nephrotic syndrome 31.2 NPHS2 ALB ACE
4 interstitial nephritis 31.2 TINAG ALB ACE
5 microvascular complications of diabetes 3 31.1 NPHS1 ALB ACE
6 chronic graft versus host disease 31.1 CD79A ALB
7 goodpasture syndrome 30.9 THSD7A PLA2R1 NPHS1 ALB
8 glomerular disease 30.9 NPHS2 NPHS1 CD79A CD2AP ALB ACE
9 membranoproliferative glomerulonephritis 30.8 NPHS1 CD79A C3 ALB
10 rapidly progressive glomerulonephritis 30.8 PLA2R1 C3 ALB
11 syphilis 30.7 CD79A ALB ACE
12 glomerulonephritis 30.7 NPHS2 NPHS1 LRPAP1 LRP2 CD79A C3
13 iga glomerulonephritis 30.7 PLA2R1 NPHS2 NPHS1 CD79A C3 ALB
14 purpura 30.6 CD79A C3 ACE
15 arteriolosclerosis 30.5 CD79A C3 ALB
16 nephrotic syndrome, type 1 30.4 NPHS2 NPHS1 CD2AP
17 urinary tract obstruction 30.4 NPHS1 ALB ACE
18 acute kidney tubular necrosis 30.4 LRP2 ALB ACE
19 nephrotic syndrome, type 2 30.4 NPHS2 NPHS1
20 angioedema 30.3 MME C3 ACE
21 obstructive nephropathy 30.2 TINAG ALB ACE
22 focal segmental glomerulosclerosis 30.2 VTN TRPC6 PODXL NPHS2 NPHS1 CD2AP
23 nephrosclerosis 30.2 NPHS2 NPHS1 ACE
24 congenital syphilis 30.2 NPHS2 NPHS1 CD79A
25 cerebral lymphoma 30.1 LRP2 CD79A
26 guillain-barre syndrome 30.1 HLA-DQA1 CD79A ALB
27 microvascular complications of diabetes 5 29.9 VTN ALB ACE
28 iga nephropathy 1 29.9 NPHS2 NPHS1 CD79A ACE
29 lipoid nephrosis 29.9 TRPC6 PODXL PLA2R1 NPHS2 NPHS1 CD79A
30 nail-patella syndrome 29.9 TRPC6 NPHS2 NPHS1 CD2AP
31 pyuria 29.8 C3 ALB
32 kidney disease 29.8 TRPC6 PECAM1 NPHS2 NPHS1 CD79A CD2AP
33 pneumonia 29.8 VTN PLA2G1B ALB ACE
34 congenital membranous nephropathy due to fetomaternal anti-neutral endopeptidase alloimmunization 12.4
35 hematuria, benign familial 12.4
36 alport syndrome 11.7
37 hepatitis b 10.6
38 autoimmune disease 10.6
39 systemic lupus erythematosus 10.6
40 orthostatic proteinuria 10.5 ALB ACE
41 epidermolysis bullosa dystrophica, autosomal dominant 10.5 C3 ALB
42 hilar lung carcinoma 10.5 MME CD79A
43 lung hilum cancer 10.5 MME CD79A
44 granulomatous hepatitis 10.5 ALB ACE
45 bladder lymphoma 10.5 MME CD79A
46 prostate lymphoma 10.5 MME CD79A
47 kidney papillary necrosis 10.5 ALB ACE
48 generalized atherosclerosis 10.5 ALB ACE
49 epiglottis neoplasm 10.5 MME CD79A
50 liver lymphoma 10.5 MME CD79A
51 bone lymphoma 10.5 MME CD79A
52 colon lymphoma 10.5 MME CD79A
53 lung lymphoma 10.5 MME CD79A
54 hypertensive encephalopathy 10.5 ALB ACE
55 severe nonproliferative diabetic retinopathy 10.5 ALB ACE
56 oligomeganephronia 10.5 NPHS2 NPHS1
57 breast lymphoma 10.5 MME CD79A
58 gray zone lymphoma 10.5 MME CD79A
59 sclerosing hepatic carcinoma 10.5 MME CD79A
60 gastrointestinal lymphoma 10.5 MME CD79A
61 pulmonary artery leiomyosarcoma 10.4 PECAM1 MME
62 ureteral disease 10.4 NPHS1 ALB ACE
63 rheumatic fever 10.4 HLA-DQA1 ALB ACE
64 renal hypertension 10.4 NPHS1 ALB ACE
65 hypersensitivity vasculitis 10.4 C3 ALB ACE
66 crescentic glomerulonephritis 10.4
67 hypersensitivity reaction type iii disease 10.4 C3 ALB ACE
68 pediatric lymphoma 10.4 MME CD79A
69 composite lymphoma 10.4 MME CD79A
70 lupus erythematosus 10.4
71 pericarditis 10.4 VTN ALB ACE
72 breast sarcoma 10.4 PECAM1 MME
73 focal segmental glomerulosclerosis 5 10.4 TRPC6 NPHS2
74 gastric lymphoma 10.4 MME CD79A ALB
75 plasma protein metabolism disease 10.4 MME CD79A ALB
76 subungual glomus tumor 10.4 PECAM1 CD2AP
77 plasma cell neoplasm 10.4 MME CD79A ALB
78 acute poststreptococcal glomerulonephritis 10.4 CD79A C3 ALB
79 hodgkin's lymphoma, lymphocytic depletion 10.3 CD79A CD2AP C3
80 angiokeratoma of fordyce 10.3 PECAM1 ACE
81 hypertensive retinopathy 10.3 ALB ACE
82 lymphatic system disease 10.3 MME CD79A ALB
83 spinal cord lymphoma 10.3 MME CD79A
84 skin hemangioma 10.3 PECAM1 ACE
85 graft-versus-host disease 10.3
86 root caries 10.3 CD79A ALB
87 testicular lymphoma 10.3 MME CD79A
88 vasculitis 10.3
89 microvascular complications of diabetes 4 10.3
90 microvascular complications of diabetes 6 10.3
91 microvascular complications of diabetes 7 10.3
92 igg4-related disease 10.3
93 hypertensive nephropathy 10.3 ALB ACE
94 otitis media 10.3 CD79A C3 ALB
95 trypanosomiasis 10.3 C3 ALB ACE
96 chronic kidney disease 10.3
97 rheumatoid arthritis 10.3
98 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.3
99 bartonellosis 10.3 PECAM1 ACE
100 sarcoidosis 1 10.2
101 x-linked alport syndrome 10.2
102 hepatitis 10.2
103 acute kidney failure 10.2
104 proliferative glomerulonephritis 10.2
105 amyloidosis 10.2
106 hypereosinophilic syndrome 10.2
107 focal segmental glomerulosclerosis 2 10.2 TRPC6 NPHS2 NPHS1 CD2AP
108 focal segmental glomerulosclerosis 1 10.2 TRPC6 NPHS2 NPHS1 CD2AP
109 frasier syndrome 10.2 TRPC6 NPHS2 NPHS1 CD2AP
110 genetic steroid-resistant nephrotic syndrome 10.2 TRPC6 NPHS2 NPHS1 CD2AP
111 denys-drash syndrome 10.2 TRPC6 NPHS2 NPHS1 CD2AP
112 breast osteosarcoma 10.2 MME CD79A
113 hepatitis c virus 10.2
114 polyradiculoneuropathy 10.1
115 glucose intolerance 10.1
116 primary biliary cirrhosis 10.1
117 hepatitis c 10.1
118 viral hepatitis 10.1
119 thyroiditis 10.1
120 constrictive pericarditis 10.1 ALB ACE
121 hypercholesterolemia, familial, 1 10.1
122 renal cell carcinoma, nonpapillary 10.1
123 thrombophilia due to thrombin defect 10.1
124 myasthenia gravis 10.1
125 thrombosis 10.1
126 autosomal recessive alport syndrome 10.1
127 mesangial proliferative glomerulonephritis 10.1
128 liver cirrhosis 10.1
129 kidney hypertrophy 10.1 PODXL NPHS2 NPHS1 ALB ACE
130 small cell cancer of the lung 10.1
131 lung cancer 10.1
132 congenital heart defects, hamartomas of tongue, and polysyndactyly 10.1
133 cysticercosis 10.1
134 canomad syndrome 10.1
135 cytomegalovirus infection 10.1
136 autoimmune pancreatitis 10.1
137 lymphocytic leukemia 10.1
138 pustulosis of palm and sole 10.1
139 psoriasis 10.1
140 diabetes mellitus, insulin-dependent 10.1 HLA-DQA1 CD79A C3 ALB ACE
141 spondyloarthropathy 1 10.0
142 exanthem 10.0
143 fanconi syndrome 10.0
144 inflammatory spondylopathy 10.0
145 graves' disease 10.0
146 hypothyroidism 10.0
147 immune-complex glomerulonephritis 10.0
148 spondylitis 10.0
149 arthritis 10.0
150 alopecia 10.0
151 anca-associated vasculitis 10.0
152 familial nephrotic syndrome 10.0 TRPC6 PODXL NPHS2 NPHS1 CD2AP
153 acute proliferative glomerulonephritis 10.0 PODXL PLA2R1 NPHS2 NPHS1 C3 ALB
154 hashimoto thyroiditis 10.0
155 celiac disease 1 10.0
156 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.0
157 branchiootic syndrome 1 10.0
158 aplastic anemia 10.0
159 myelodysplastic syndrome 10.0
160 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 10.0
161 renal fibrosis 10.0
162 lymphoma 10.0
163 polycystic kidney disease 10.0
164 malignant hypertension 10.0
165 neutropenia 10.0
166 adenocarcinoma 10.0
167 anti-basement membrane glomerulonephritis 10.0
168 pancreatitis 10.0
169 connective tissue disease 10.0
170 diabetes mellitus 10.0
171 pulmonary embolism 10.0
172 tremor 10.0
173 thrombotic microangiopathy 10.0
174 thrombocytopenic purpura, autoimmune 10.0
175 uremia 10.0
176 fibrosis of extraocular muscles, congenital, 1 9.9
177 leukemia, chronic lymphocytic 9.9
178 neurofibromatosis, type iv, of riccardi 9.9
179 immune deficiency disease 9.9
180 sjogren syndrome 9.9
181 thymoma, familial 9.9
182 leukemia, acute myeloid 9.9
183 leukemia, acute lymphoblastic 9.9
184 dermatomyositis 9.9
185 hydronephrosis 9.9
186 polyneuropathy 9.9
187 thrombocytopenia 9.9
188 vascular disease 9.9
189 churg-strauss syndrome 9.9
190 thymoma 9.9
191 ureteral obstruction 9.9
192 demyelinating polyneuropathy 9.9
193 hemolytic anemia 9.9
194 bullous pemphigoid 9.9
195 herpes zoster 9.9
196 47,xyy 9.9
197 hypoadrenalism 9.9
198 hypoaldosteronism 9.9
199 hypocomplementemic urticarial vasculitis 9.9
200 mercury poisoning 9.9
201 retroperitoneal fibrosis 9.9
202 igg4-related kidney disease 9.9
203 vulvar benign neoplasm 9.9 PECAM1 CD2AP
204 immunoglobulin a deficiency 1 9.9
205 dermatitis herpetiformis, familial 9.9
206 systemic lupus erythematosus 2 9.9
207 endocarditis 9.9
208 portal hypertension 9.9
209 melanoma 9.9
210 idiopathic interstitial pneumonia 9.9
211 pulmonary fibrosis 9.9
212 dermatitis herpetiformis 9.9
213 crohn's disease 9.9
214 nodular regenerative hyperplasia 9.9
215 esophageal cancer 9.8
216 kaposi sarcoma 9.8
217 scleroderma, familial progressive 9.8
218 ascites, chylous 9.8
219 myeloma, multiple 9.8
220 vascular hyalinosis 9.8
221 fabry disease 9.8
222 helicobacter pylori infection 9.8
223 wilms tumor 5 9.8
224 homocysteinemia 9.8
225 gastrointestinal stromal tumor 9.8
226 granulomatosis with polyangiitis 9.8
227 cholangitis, primary sclerosing 9.8
228 hydrops, lactic acidosis, and sideroblastic anemia 9.8
229 deficiency anemia 9.8
230 autoimmune glomerulonephritis 9.8
231 autosomal recessive disease 9.8
232 metabolic acidosis 9.8
233 ptosis 9.8
234 lymphoproliferative syndrome 9.8
235 autosomal dominant alport syndrome 9.8
236 castleman disease 9.8
237 sialadenitis 9.8
238 thrombotic thrombocytopenic purpura 9.8
239 pulmonary alveolar proteinosis 9.8
240 leukemia 9.8
241 pancytopenia 9.8
242 pulmonary sarcoidosis 9.8
243 sclerosing cholangitis 9.8
244 urticaria 9.8
245 hyperuricemia 9.8
246 cholecystitis 9.8
247 rectum cancer 9.8
248 autoimmune hepatitis 9.8
249 relapsing polychondritis 9.8
250 agammaglobulinemia 9.8
251 benign mesothelioma 9.8
252 dermatitis 9.8
253 acquired polycythemia 9.8
254 antiphospholipid syndrome 9.8
255 neurilemmoma 9.8
256 mixed connective tissue disease 9.8
257 systemic scleroderma 9.8
258 hypokalemia 9.8
259 chronic inflammatory demyelinating polyradiculoneuropathy 9.8
260 peripheral nervous system disease 9.8
261 lymphopenia 9.8
262 severe combined immunodeficiency 9.8
263 acquired immunodeficiency syndrome 9.8
264 b-cell lymphoma 9.8
265 hyperthyroidism 9.8
266 polycythemia 9.8
267 collagen disease 9.8
268 myeloid leukemia 9.8
269 neuropathy 9.8
270 autosomal dominant polycystic kidney disease 9.8
271 macroglobulinemia 9.8
272 cholangitis 9.8
273 meningitis 9.8
274 polyarteritis nodosa 9.8
275 48,xyyy 9.8
276 acute graft versus host disease 9.8
277 allergic angiitis 9.8
278 fibrillary glomerulonephritis 9.8
279 microscopic polyangiitis 9.8
280 foot drop 9.8
281 systemic autoimmune disease 9.8
282 obsolete: rapidly progressive glomerulonephritis 9.8
283 argyria 9.8
284 rare tumor 9.8
285 colorectal cancer 9.7
286 hepatocellular carcinoma 9.7
287 preauricular fistulae, congenital 9.7
288 yellow nail syndrome 9.7
289 ocular cicatricial pemphigoid 9.7
290 porphyria cutanea tarda, type i 9.7
291 porphyria cutanea tarda 9.7
292 pulmonary fibrosis, idiopathic 9.7
293 thrombophilia due to activated protein c resistance 9.7
294 renal hypodysplasia/aplasia 1 9.7
295 alport syndrome 2, autosomal recessive 9.7
296 fibrosclerosis, multifocal 9.7
297 renal glucosuria 9.7
298 lymphoma, hodgkin, classic 9.7
299 familial mediterranean fever 9.7
300 alport syndrome 1, x-linked 9.7
301 hemophilia b 9.7
302 ataxia and polyneuropathy, adult-onset 9.7
303 lymphoma, non-hodgkin, familial 9.7
304 mycobacterium tuberculosis 3 9.7
305 alpha-1-antitrypsin deficiency 9.7
306 aspergillosis 9.7
307 hyperprolactinemia 9.7
308 nephrotic syndrome, type 12 9.7
309 encephalopathy, progressive, early-onset, with episodic rhabdomyolysis 9.7
310 diffuse large b-cell lymphoma 9.7
311 marginal zone b-cell lymphoma 9.7
312 splenic marginal zone lymphoma 9.7
313 secondary progressive multiple sclerosis 9.7
314 paroxysmal nocturnal hemoglobinuria 9.7
315 meningoencephalitis 9.7
316 pre-eclampsia 9.7
317 chronic pyelonephritis 9.7
318 filariasis 9.7
319 t cell deficiency 9.7
320 disseminated intravascular coagulation 9.7
321 chlamydia 9.7
322 pyelonephritis 9.7
323 portal vein thrombosis 9.7
324 dysgammaglobulinemia 9.7
325 iron deficiency anemia 9.7
326 hemosiderosis 9.7
327 retroperitoneal sarcoma 9.7
328 secondary hyperparathyroidism 9.7
329 telangiectasis 9.7
330 dilated cardiomyopathy 9.7
331 porphyria 9.7
332 hyperparathyroidism 9.7
333 adult-onset still's disease 9.7
334 panniculitis 9.7
335 rheumatic disease 9.7
336 thrombocytopenia due to platelet alloimmunization 9.7
337 neuroendocrine tumor 9.7
338 squamous cell carcinoma 9.7
339 cannabis dependence 9.7
340 enthesopathy 9.7
341 iron metabolism disease 9.7
342 gangliocytoma 9.7
343 thrombophilia 9.7
344 retinal vascular disease 9.7
345 transitional cell carcinoma 9.7
346 synovitis 9.7
347 hemoglobinopathy 9.7
348 myelitis 9.7
349 choriocarcinoma 9.7
350 cranial nerve palsy 9.7
351 linitis plastica 9.7
352 gastritis 9.7
353 heart valve disease 9.7
354 seminoma 9.7
355 diffuse glomerulonephritis 9.7
356 ganglioneuroma 9.7
357 hemoglobinuria 9.7
358 hypersplenism 9.7
359 endometrial small cell carcinoma 9.7
360 scabies 9.7
361 intracranial hypertension 9.7
362 cannabis abuse 9.7
363 tuberculous peritonitis 9.7
364 muscular dystrophy 9.7
365 amyloidosis aa 9.7
366 dense deposit disease 9.7
367 grover's disease 9.7
368 growth hormone deficiency 9.7
369 heparin-induced thrombocytopenia 9.7
370 medullary sponge kidney 9.7
371 meningococcemia 9.7
372 neisseria meningitidis infection 9.7
373 post-transplant lymphoproliferative disease 9.7
374 testicular seminoma 9.7
375 tetraploidy 9.7
376 transverse myelitis 9.7
377 triploidy 9.7
378 cryptogenic cirrhosis 9.7
379 back pain 9.7
380 dysphagia 9.7
381 headache 9.7
382 rare hereditary hemochromatosis 9.7
383 cerebral sinovenous thrombosis 9.7
384 acute liver failure 9.7
385 refractory cytopenia with multilineage dysplasia 9.7
386 laminopathy 9.7
387 atrial standstill 1 9.7
388 bladder cancer 9.7
389 cryoglobulinemia, familial mixed 9.7
390 multiple sclerosis 9.7
391 exostoses, multiple, type i 9.7
392 exostoses, multiple, type ii 9.7
393 external auditory canal, bilateral atresia of, with congenital vertical talus 9.7
394 factor viii deficiency 9.7
395 diaphragmatic hernia, congenital 9.7
396 hypertriglyceridemia, familial 9.7
397 hypoparathyroidism, sensorineural deafness, and renal disease 9.7
398 keratitis, hereditary 9.7
399 mesothelioma, malignant 9.7
400 myositis 9.7
401 nephrolithiasis, calcium oxalate 9.7
402 pityriasis rubra pilaris 9.7
403 polyposis, skin pigmentation, alopecia, and fingernail changes 9.7
404 prostate cancer 9.7
405 dowling-degos disease 1 9.7
406 retinal detachment 9.7
407 schistosoma mansoni infection, susceptibility/ 9.7
408 digeorge syndrome 9.7
409 vitiligo-associated multiple autoimmune disease susceptibility 6 9.7
410 anemia, autoimmune hemolytic 9.7
411 australia antigen 9.7
412 cystinuria 9.7
413 glycogen storage disease ii 9.7
414 schimke immunoosseous dysplasia 9.7
415 mucopolysaccharidosis, type vi 9.7
416 muscular dystrophy, limb-girdle, autosomal recessive 2 9.7
417 mycosis fungoides 9.7
418 myelofibrosis 9.7
419 proteasome-associated autoinflammatory syndrome 1 9.7
420 graves disease 1 9.7
421 werner syndrome 9.7
422 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 9.7
423 hemophilia a 9.7
424 kearns-sayre syndrome 9.7
425 asthma 9.7
426 cd4/cd8 t-cell ratio 9.7
427 yemenite deaf-blind hypopigmentation syndrome 9.7
428 astigmatism 9.7
429 macular degeneration, age-related, 1 9.7
430 cervical cancer 9.7
431 langerhans cell histiocytosis 9.7
432 vitiligo-associated multiple autoimmune disease susceptibility 1 9.7
433 lymphangioleiomyomatosis 9.7
434 nasopharyngeal carcinoma 9.7
435 creatinine clearance quantitative trait locus 9.7
436 psoriatic arthritis 9.7
437 mycobacterium tuberculosis 1 9.7
438 endometrial cancer 9.7
439 leukemia, chronic myeloid 9.7
440 myocardial infarction 2 9.7
441 histiocytoma, angiomatoid fibrous 9.7
442 lung cancer susceptibility 3 9.7
443 colorectal cancer 9 9.7
444 gastric cancer 9.7
445 focal segmental glomerulosclerosis 6 9.7
446 leukemia, acute lymphoblastic 3 9.7
447 nephrotic syndrome, type 11 9.7
448 mucopolysaccharidosis-plus syndrome 9.7
449 nephrotic syndrome, type 19 9.7
450 peripheral vascular disease 9.7
451 cryptogenic organizing pneumonia 9.7
452 inflammatory bowel disease 9.7
453 small cell carcinoma 9.7
454 anaplastic large cell lymphoma 9.7
455 peripheral t-cell lymphoma 9.7
456 rheumatic heart disease 9.7
457 peripheral artery disease 9.7
458 hemorrhagic cystitis 9.7
459 follicular lymphoma 9.7
460 immunoglobulin alpha deficiency 9.7
461 diffuse alopecia areata 9.7
462 colitis 9.7
463 progressive familial intrahepatic cholestasis 9.7
464 acquired von willebrand syndrome 9.7
465 angioimmunoblastic t-cell lymphoma 9.7
466 thalassemia 9.7
467 bacterial infectious disease 9.7
468 charcot-marie-tooth disease 9.7
469 rickets 9.7
470 abducens nerve disease 9.7
471 tooth disease 9.7
472 hemiplegia 9.7
473 sarcoma 9.7
474 spondyloarthropathy 9.7
475 tetanus 9.7
476 chagas disease 9.7
477 goiter 9.7
478 common variable immunodeficiency 9.7
479 hepatitis a 9.7
480 acute leukemia 9.7
481 nephrocalcinosis 9.7
482 leiomyoma 9.7
483 mikulicz disease 9.7
484 acute cystitis 9.7
485 gout 9.7
486 diarrhea 9.7
487 exocrine pancreatic insufficiency 9.7
488 ehlers-danlos syndrome 9.7
489 cholestasis 9.7
490 biliary atresia 9.7
491 facial paralysis 9.7
492 amenorrhea 9.7
493 schistosomiasis 9.7
494 alcoholic liver cirrhosis 9.7
495 renal tubular acidosis 9.7
496 plasmodium malariae malaria 9.7
497 gonadal dysgenesis 9.7
498 hereditary angioedema 9.7
499 cystitis 9.7
500 ichthyosis 9.7
501 retinal vein occlusion 9.7
502 leiomyosarcoma 9.7
503 drug-induced hepatitis 9.7
504 hepatitis d 9.7
505 ascending colon cancer 9.7
506 myeloproliferative neoplasm 9.7
507 colon adenocarcinoma 9.7
508 arteriosclerosis 9.7
509 central retinal vein occlusion 9.7
510 bronchiolitis obliterans 9.7
511 endometriosis 9.7
512 acute pancreatitis 9.7
513 cryoglobulinemia 9.7
514 bronchiolitis 9.7
515 pulmonary tuberculosis 9.7
516 anuria 9.7
517 lipid metabolism disorder 9.7
518 rhabdomyosarcoma 9.7
519 ischemia 9.7
520 thymic carcinoma 9.7
521 histiocytosis 9.7
522 carotid artery thrombosis 9.7
523 systemic mastocytosis 9.7
524 turner syndrome 9.7
525 mastocytosis 9.7
526 gastric adenocarcinoma 9.7
527 liver disease 9.7
528 secondary syphilis 9.7
529 hyperglycemia 9.7
530 myopathy 9.7
531 histiocytoma 9.7
532 spindle cell sarcoma 9.7
533 coronary stenosis 9.7
534 schnitzler syndrome 9.7
535 hepatitis e 9.7
536 fibrous histiocytoma 9.7
537 exudative glomerulonephritis 9.7
538 thyroid gland disease 9.7
539 aortitis 9.7
540 human immunodeficiency virus infectious disease 9.7
541 combined t cell and b cell immunodeficiency 9.7
542 adenoma 9.7
543 juvenile rheumatoid arthritis 9.7
544 kimura disease 9.7
545 malignant pleural mesothelioma 9.7
546 peptic ulcer disease 9.7
547 cocaine abuse 9.7
548 peritonitis 9.7
549 intestinal obstruction 9.7
550 influenza 9.7
551 mucormycosis 9.7
552 lung disease 9.7
553 ulcerative colitis 9.7
554 chickenpox 9.7
555 neuromyelitis optica 9.7
556 carotid artery dissection 9.7
557 bacterial meningitis 9.7
558 bronchiectasis 9.7
559 encephalitis 9.7
560 neurofibroma 9.7
561 miliary tuberculosis 9.7
562 hemophilia 9.7
563 limb-girdle muscular dystrophy 9.7
564 17q12 recurrent deletion syndrome 9.7
565 autoimmune encephalitis 9.7
566 c1q nephropathy 9.7
567 cerebellar degeneration 9.7
568 chromosomal triplication 9.7
569 cytokine deficiency 9.7
570 granulocytopenia 9.7
571 homologous wasting disease 9.7
572 horseshoe kidney 9.7
573 neuromyelitis optica spectrum disorder 9.7
574 polymyositis 9.7
575 rasmussen johnsen thomsen syndrome 9.7
576 warthin tumor 9.7
577 depression 9.7
578 aneurysm 9.7
579 cerebral aneurysms 9.7
580 paraneoplastic syndromes 9.7
581 immuno-osseous dysplasia 9.7
582 rare hemorrhagic disorder 9.7
583 rasmussen subacute encephalitis 9.7
584 familial intrahepatic cholestasis 9.7
585 pauci-immune glomerulonephritis 9.7
586 polyendocrinopathy 9.7
587 hypertension, essential 9.6 TRPC6 PLA2G1B PECAM1 NPHS2 NPHS1 MME

Graphical network of the top 20 diseases related to Membranous Nephropathy:



Diseases related to Membranous Nephropathy

Symptoms & Phenotypes for Membranous Nephropathy

Clinical features from OMIM:

614692

GenomeRNAi Phenotypes related to Membranous Nephropathy according to GeneCards Suite gene sharing:

26 (showing 1, show less)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 ALB C3 CD79A HLA-DQA1 LRP2 PLA2G1B

MGI Mouse Phenotypes related to Membranous Nephropathy:

45 (showing 3, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.97 ACE ALB C3 CD2AP CD79A LRP2
2 liver/biliary system MP:0005370 9.5 ACE ALB C3 CD79A MME PECAM1
3 renal/urinary system MP:0005367 9.32 ACE ALB C3 CD2AP CD79A LRP2

Drugs & Therapeutics for Membranous Nephropathy

Drugs for Membranous Nephropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 115, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
2
Mycophenolic acid Approved Phase 4 24280-93-1 446541
3
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
4
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
5
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
6
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
7 Immunoglobulin A Phase 4
8 Tripterygium Phase 4
9 Antibiotics, Antitubercular Phase 4
10 Antitubercular Agents Phase 4
11 Anti-Infective Agents Phase 4
12 Anti-Bacterial Agents Phase 4
13 Calcineurin Inhibitors Phase 4
14 Immunologic Factors Phase 4
15 Dermatologic Agents Phase 4
16 Cyclosporins Phase 4
17 Antifungal Agents Phase 4
18 Pharmaceutical Solutions Phase 4
19 Neurotransmitter Agents Phase 4
20 Endorphins Phase 4
21 Antiviral Agents Phase 4
22 Antihypertensive Agents Phase 4
23 Angiotensin Receptor Antagonists Phase 4
24 Angiotensin II Type 1 Receptor Blockers Phase 4
25 Giapreza Phase 4
26 Angiotensinogen Phase 4
27
Deflazacort Approved, Investigational Phase 3 14484-47-0
28
Chlorambucil Approved Phase 3 305-03-3 2708
29
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
30
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
31
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
32
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
33
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
34 Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
35
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
36
Pentoxifylline Approved, Investigational Phase 3 6493-05-6 4740
37
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
38 HIV Protease Inhibitors Phase 3
39
protease inhibitors Phase 3
40 Anticholesteremic Agents Phase 3
41 Hypolipidemic Agents Phase 3
42 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 3
43 Adrenergic Antagonists Phase 3
44 Serine Proteinase Inhibitors Phase 3
45 Mineralocorticoids Phase 3
46 Adrenergic beta-Antagonists Phase 3
47 Vasoconstrictor Agents Phase 3
48 Mineralocorticoid Receptor Antagonists Phase 3
49 Natriuretic Agents Phase 3
50 Adrenergic Agents Phase 3
51 Lipid Regulating Agents Phase 3
52 Diuretics, Potassium Sparing Phase 3
53 Antimetabolites Phase 3
54 diuretics Phase 3
55 Alkylating Agents Phase 3
56 Immunosuppressive Agents Phase 3
57 Anti-Inflammatory Agents Phase 3
58 Antineoplastic Agents, Hormonal Phase 3
59 glucocorticoids Phase 3
60 Methylprednisolone Acetate Phase 3
61 Antiemetics Phase 3
62 Gastrointestinal Agents Phase 3
63 Autonomic Agents Phase 3
64 Neuroprotective Agents Phase 3
65 Protective Agents Phase 3
66 Platelet Aggregation Inhibitors Phase 3
67 Free Radical Scavengers Phase 3
68 Antioxidants Phase 3
69 Phosphodiesterase Inhibitors Phase 3
70 Vasodilator Agents Phase 3
71 Radiation-Protective Agents Phase 3
72
Serine Investigational, Nutraceutical Phase 3 56-45-1 5951
73
Zinc Approved, Investigational Phase 2 7440-66-6 32051
74
Cosyntropin Approved Phase 2 16960-16-0 16129617
75
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
76
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
77
Methimazole Approved Phase 1, Phase 2 60-56-0 1349907
78
rituximab Approved Phase 2 174722-31-7 10201696
79 Adrenocorticotropin zinc Phase 2
80 Vaccines Phase 1, Phase 2
81 Antirheumatic Agents Phase 2
82 Antibodies Phase 2
83 Immunoglobulins Phase 2
84 Antineoplastic Agents, Immunological Phase 2
85 Antibodies, Monoclonal Phase 2
86
Losartan Approved 114798-26-4 3961
87
Clarithromycin Approved 81103-11-9 84029
88
Amoxicillin Approved, Vet_approved 26787-78-0 33613
89
Lansoprazole Approved, Investigational 103577-45-3 3883
90
Dexlansoprazole Approved, Investigational 138530-94-6, 103577-45-3 9578005
91
tannic acid Approved 1401-55-4
92
Benzocaine Approved, Investigational 1994-09-7, 94-09-7 2337
93
Triamcinolone Approved, Vet_approved 124-94-7 31307
94
Calcium Approved, Nutraceutical 7440-70-2 271
95
Ergocalciferol Approved, Nutraceutical 50-14-6 5280793
96
Vitamin D Approved, Nutraceutical, Vet_approved 1406-16-2
97
Vitamin D3 Approved, Nutraceutical 67-97-0 6221 5280795
98 Anti-Arrhythmia Agents
99 Autoantibodies
100 Calcium, Dietary
101 Cytochrome P-450 CYP3A Inhibitors
102 Proton Pump Inhibitors
103 Cytochrome P-450 Enzyme Inhibitors
104 Anti-Ulcer Agents
105 Antacids
106 Vitamins
107 Trace Elements
108 Micronutrients
109 Nutrients
110 Ergocalciferols
111 Calciferol
112 Vitamin D2
113 Triamcinolone diacetate
114 Triamcinolone hexacetonide
115 triamcinolone acetonide

Interventional clinical trials:

(showing 74, show less)
# Name Status NCT ID Phase Drugs
1 Mycophenolate Mofetil and Tacrolimus vs Tacrolimus Alone for the Treatment of Idiopathic Membranous Glomerulonephritis (IMG) Completed NCT00843856 Phase 4 tacrolimus;tacrolimus and mycophenolate mofetil
2 A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN) Completed NCT01386554 Phase 4 Repository Corticotropin Injection;Placebo
3 To Compare the Efficacy and Safety of TW vs Valsartan in the MN Completed NCT00518219 Phase 4 TW
4 Tacrolimus for the Treatment of Systemic Lupus Erythematosus With Membranous Nephritis Completed NCT00125307 Phase 4 tacrolimus
5 Prospective Study Evaluating the Effect of Repository Corticotropin in the Treatment of Various Nephrotic Syndromes Completed NCT01021540 Phase 4 Repository corticotrophin
6 The Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR) Completed NCT01129284 Phase 4 ACTHAR gel
7 Tacrolimus vs Prednisolone for the Treatment Minimal Change Disease Completed NCT00982072 Phase 4 tacrolimus;prednisolone
8 A Prospective Randomized, Controlled Trial of Mycophenolate Mofetil Plus Steroid in the Treatment Of Patients With Progressive Idiopathic Membranous Nephropathy Recruiting NCT03170323 Phase 4 Mycophenolate Mofetil;Cyclosporins
9 Changes in Autoreactive Memory B Cells as Biomarker of Response to Adrenocorticotropic Hormone in Patients With Membranous Nephropathy Recruiting NCT03025828 Phase 4 ACTHar
10 A Randomized Open-label Study to Evaluate the Efficacy and Safety of Tacrolimus and Corticosteroids in Comparison With Mycophenolate Mofetil and Corticosteroids in Subjects With Class III/IV±V Lupus Nephritis Recruiting NCT02630628 Phase 4 Tacrolimus;Mycophenolate mofetil
11 The Therapy of Tacrolimus Combined With Entecavir on HBV Associated Glomerulonephritis : A Multicenter, Prospective, Randomized, Controlled, Single-blind Trial. Recruiting NCT03062813 Phase 4 Tacrolimus &entecavir;placebo & entecavir
12 A Multicenterer, Comparative Safety Andof ACTHar Gel Alone or in Cwith oe Urinary in Patients Positive Fibrillary Glomerulopathy Recruiting NCT04080076 Phase 4 Acthar 80 UNT/ML Injectable Solution;Tacrolimus capsule
13 Acthar for Treatment of Post-transplant FSGS Not yet recruiting NCT02399462 Phase 4 Acthar
14 Aldosterone Breakthrough During Diovan (Valsartan), Tekturna (Aliskiren), and Combination (Valsartan+Aliskiren) Anti-hypertensive Therapy in Patients With Proteinuric Kidney Disease Terminated NCT01129557 Phase 4 Aliskiren;Valsartan
15 An Open Label Randomized Phase IV Study of the Safety and Efficacy of ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis Withdrawn NCT01926054 Phase 4 Acthar gel
16 A Randomized Controlled Multi-center Trial of Mycophenolate Mofetil for the Patient With High Risk Membranous Nephropathy Unknown status NCT01282073 Phase 3 Mycophenolate mofetil, low dose steroid;Cyclosporin, low dose steroid
17 Prospective Randomized Multicentric Open Label Study to Evaluate Rituximab Treatment for Idiopathic Membranous Nephropathy (IMN) Unknown status NCT01508468 Phase 3 symptomatic treatment (Converting Enzyme inhibitor, Angiotensin II, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin);experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab)
18 Phase 3 Study of Tacrolimus Combined With Prednisone Treatment of Idiopathic Membranous Nephropathy and Nephrotic Syndrome Completed NCT00362531 Phase 2, Phase 3 tacrolimus combined with prednisone
19 A Prospective Randomized Open-label Study to Compare Mycophenolate Mofetil and Corticosteroid With Conventional Immunosuppressive Treatment on Proteinuria in Idiopathic Membranous Nephropathy (MN) and Focal Segmental Glomerulosclerosis (FSGS) Completed NCT00404833 Phase 3 prednisolone and mycophenolate mofetil;prednisolone and chlorambucil
20 Treatment of Patients With Membranous Nephropathy and Renal Insufficiency With Mycophenolate Mofetil and Prednisone: a Pilot Study Completed NCT00135967 Phase 2, Phase 3 mycophenolate mofetil orally 1000 mg twice a day (BID);prednisone 0,5 mg/kg orally on alternate days;intravenous (i.v.) methylprednisolone 1000 mg, total 9
21 Treatment of Patients With Idiopathic Membranous Nephropathy at Risk for Renal Insufficiency: Comparison of Early Versus Late Start of Immunosuppressive Therapy Completed NCT00135954 Phase 3 Cyclophosphamide and steroids
22 The Use of Rituximab in the Treatment of Idiopathic Membranous Nephropathy Completed NCT00425217 Phase 2, Phase 3 Rituximab
23 "A Randomized Controlled Trial of Rituximab Versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (IMN)" Completed NCT01180036 Phase 2, Phase 3 Rituximab;Cyclosporine
24 A Prospective Randomized Open-label Study to Compare Mycophenolate Mofetil and A Prospective Randomized Open-label Study to Compare Mycophenolate Mofetil and Corticosteroid With Tacrolimus and Corticosteroid as Immunosuppressive Treatment for Lupus Membranous Nephritis Completed NCT00404794 Phase 3 prednisolone and mycophenolate mofetil;prednisolone and tacrolimus
25 Clinical Efficacy of Pentoxifylline on Patients With Primary Nephrotic Syndrome Completed NCT00354731 Phase 3 pentoxifylline;Corticosteroid
26 European Multicenter and Open-Label Controlled Randomized Trial to Evaluate the Efficacy of Sequential Treatment With Tacrolimus-Rituximab Versus Steroids Plus Cyclophosphamide in Patients With Primary Membranous Nephropathy (The STARMEN Study) Active, not recruiting NCT01955187 Phase 3 TACROLIMUS;RITUXIMAB;METHYLPREDNISOLONE;CYCLOPHOSPHAMIDE
27 A Randomized Controlled Trial of Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy Active, not recruiting NCT03018535 Phase 3 Rituximab;Methylprednisolone;Cyclophosphamide
28 Clinical Efficacy of Combined Pentoxifylline and Conventional Immunosuppressive Regimens on Patients With Rapidly Progressive Glomerulonephritis Terminated NCT00354198 Phase 3 pentoxifylline;corticosteroids
29 Phase II Trial Investigating the Safety and Feasibility of Peptide GAM Immunoadsorption in Anti-PLA2R Positive Autoimmune Membranous Nephropathy Unknown status NCT03255447 Phase 2
30 Opportunity, Validity and Security of Steroids Plus Cyclosporin Therapy for Patients of Idiopathic Membranous Nephropathy : A Prospective, Randomized, Controlled, Multi-Center Clinical Trial Unknown status NCT02173106 Phase 2 steroid & Cyclosporin
31 A Phase 2 Study to Evaluate the Safety and Effect on Proteinuria of OMS721 in Subjects With IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, or C3 Glomerulopathy Including Dense Deposit Disease Unknown status NCT02682407 Phase 2
32 Treatment With Synthetic Adrenocorticotropic Hormone (ACTH) in Patients With Membranous Nephropathy and High Risk for Renal Failure. A Pilot Study Completed NCT00694863 Phase 2 tetracosactide hexacetaat
33 Sirolimus Therapy in Idiopathic and Lupus Membranous Nephropathy Completed NCT00050713 Phase 2 Sirolimus
34 A Dose-finding Pilot Study of ACTH (Adrenocorticotropic Hormone) on the Proteinuria and Serum Lipoprotein Profile in Patients With Idiopathic Membranous Nephropathy (MN) Completed NCT01093157 Phase 1, Phase 2 Adrenocorticotrophic hormone ACTH
35 BEL116472. A 2 Year Mechanistic Study of Belimumab in Idiopathic Membranous Glomerulonephropathy Completed NCT01610492 Phase 2 belimumab
36 Immunosuppressive Drug Therapy in Membranous Lupus Nephropathy Completed NCT00001212 Phase 2 prednisone;cyclophosphamide;cyclosporin A
37 B Cell Depletion With the Anti-CD20 Monoclonal Antibody Rituximab in the Treatment of Graves' Disease Completed NCT00150111 Phase 1, Phase 2 Methimazole;Rituximab
38 Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy Recruiting NCT00977977 Phase 2 Rituximab Infusion;Oral Cyclosporine
39 A Phase Ib/IIa, Open-Label, Multicenter Clinical Trial to Assess Safety and Efficacy of the Human Anti-CD38 Antibody MOR202 in Anti-PLA2R Antibody Positive Membranous Nephropathy (aMN) Recruiting NCT04145440 Phase 1, Phase 2 MOR202
40 A Phase 2 Study to Evaluate the Safety and Biologic Activity of APL- 2 in Patients With IgA Nephropathy, Lupus Nephritis, Primary Membranous Nephropathy, or C3 Glomerulopathy (C3 Glomerulonephritis and Dense Deposit Disease) Active, not recruiting NCT03453619 Phase 2 APL-2
41 A Phase 2, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Filgotinib and GS-9876 in Subjects With Lupus Membranous Nephropathy (LMN) Active, not recruiting NCT03285711 Phase 2 Filgotinib;Lanraplenib;Filgotinib placebo;Lanreplenib placebo
42 A Randomized, Treatment Open-label, Dose-blinded Parallel Group, Three Arm, Proof-of-concept Clinical Trial to Investigate the Efficacy and Safety of LNP023 Compared With Rituximab in the Treatment of Subjects With Idiopathic Membranous Nephropathy Not yet recruiting NCT04154787 Phase 2 LNP023;Rituximab
43 Personalized Medicine for Membranous Nephropathy Not yet recruiting NCT03804359 Phase 2 Rituximab
44 Efficacy of Belimumab and Rituximab Compared to Rituximab Alone for the Treatment of Primary Membranous Nephropathy (ITN080AI) Not yet recruiting NCT03949855 Phase 2 Belimumab;Placebo for Belimumab;Rituximab
45 BEL114674: A 2 Year Study of Efficacy and Safety of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy Withdrawn NCT01762852 Phase 2 Belimumab 10 mg;Placebo
46 A Dose-Finding Pilot Study of ACTH on the Serum Lipoprotein Profile and Proteinuria in Patients With Idiopathic Membranous Nephropathy (MN) Completed NCT00805753 Phase 1 ACTH
47 A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases Completed NCT02639260 Phase 1 N-acetyl-mannosamine (ManNAc)
48 A Randomized, Two-Arm, Parallel Group Study of the Safety, Pharmacokinetics, and Pharmacodynamics of TRU-015 Added to Standard Therapy in Subjects With Membranous Nephropathy Secondary to Systemic Lupus Erythematosus Terminated NCT00479622 Phase 1 TRU-015
49 Efficacy and Safety Evaluation of QingReMoShen Granule in the Treatment of Idiopathic Membranous Nephropathy : A Randomized Double-Blind Controlled Clinical Study Unknown status NCT01845688 Losartan Tablets & QingReMoShen Granule;Losartan Tablets & Placebo Granule
50 Mechanism Research of Traditional Chinese Medicine (the Comprehensive Treatment Regimen) in Treating Idiopathic Membranous Nephropathy by Genomewide Association Studies Unknown status NCT01799460 The Comprehensive Treatment Regimen of Traditional Chinese Medicine;The immunosuppressive agents
51 A Prospective, Multi-center Study of the Chinese Medicine for the Treatment of MDR Membranous Nephropathy in the Traditional Chinese Medicine (a Herbal Formula for Invigorating Spleen and Benefiting qi and Promoting Blood Circulation) Unknown status NCT02610595 Jianpixiaozhong particles and Wuse Dietotherapy
52 Safety and Efficacy of Combination Acthar Gel and Tacrolimus in the Treatment of Steroid Resistant Nephrotic Syndrome Unknown status NCT03042637 Acthar Gel and Tacrolimus
53 Phospholipase A2 Receptor (PLA2R1) Autoantibodies in Membranous Nephropathy in Kidney Transplantation Unknown status NCT01897961
54 Tacrolimus Treatment of Patients With Idiopathic Completed NCT00302523 Tacrolimus
55 Research Institute of Nephrology, Jinling Hospital Completed NCT01161459 Tripterygium wilfordii;FK506
56 Efficacy and Safety of Rituximab in Patients With Refractory Primary Membranous Nephropathy Completed NCT03880643
57 Research Network for Neonatal Diseases Induced by Tissular Fetomaternal Alloimmunization Completed NCT00199628
58 Prospective Study of the Effects of Helicobacter Pylori Eradication on Renal Functions and Proteinuria in Patients With Membranous Nephropathy Completed NCT00983034 lansoprazole, amoxicillin, clarithromycin
59 Rituximab in the Treatment of Idiopathic Membranous Nephropathy Completed NCT00405340 Early Phase 1 Rituximab
60 Evaluation of Clinical Efficacy of Pentoxifylline on Patients With Glomerulonephritis Completed NCT00154661 pentoxifylline
61 Study of the Role of Tissular Maternofetal Alloimmunization in Placentation Pathologies Completed NCT00456118
62 Pilot Study: Efficacy and Safety of Vitamin D Supplementation in Glomerular Disease Completed NCT01835639
63 A Prospective Cohort Study of Membranous Nephropathy-associated Serological Antibody in Prediction of the Prognosis of Idiopathic Membranous Nephropathy Recruiting NCT03475602
64 Random, Open, Control and Monocentric Clinical Research on Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy (IMN) Recruiting NCT03549663 Tacrolimus;Prednisone
65 Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy: A Randomized, Open, Controlled, Multicenter Clinical Trial Recruiting NCT03864250 Tacrolimus;Prednisone
66 Diagnostic and Prognostic Value of Miss-1 Study in Children and Adult With Nephrotic Syndrome MISSNEPHROTIQUE Recruiting NCT03592030
67 Studies of Immunologically-Mediated Kidney Diseases Recruiting NCT00001979
68 PLA2R Autoreactive B-Cell Subsets and Immune Cell Monitoring in Membranous Nephropathy: Identification of Outcome Predictors and Novel Insights Into Disease Pathogenesis Recruiting NCT04095156
69 Nephrotic Syndrome Study Network Under the Rare Diseases Clinical Research Network Recruiting NCT01209000
70 Indication and Response to Immunosuppressive Treatment in Membranous Nephropathy : Role of Anti-mouse PLA2R1 ELISA Recruiting NCT02199145
71 Multicenter Prospective Cohort of Kidney Biopsy for Glomerular Disease Research Recruiting NCT03929887
72 The Efficacy of Prednisone Alone and Combination Therapy With Methylprednisolone and Cyclophosphamide in the Treatment of Membranous Nephropathy in Stage I. Not yet recruiting NCT03466801 Prednisone;MP and CTX
73 Different Histopathological Patterns in Patients With HCV Nephropathy Not yet recruiting NCT03476031
74 A Pilot Study to Evaluate the Antiproteinuric Effect of Renin Inhibition With Aliskiren in Patients With Idiopathic Membranous Nephropathy Withdrawn NCT01093781 Aliskiren

Search NIH Clinical Center for Membranous Nephropathy

Cochrane evidence based reviews: glomerulonephritis, membranous

Genetic Tests for Membranous Nephropathy

Genetic tests related to Membranous Nephropathy:

# Genetic test Affiliating Genes
1 Membranous Nephropathy 29

Anatomical Context for Membranous Nephropathy

MalaCards organs/tissues related to Membranous Nephropathy:

40
Kidney, T Cells, B Cells, Liver, Lung, Thyroid, Bone

Publications for Membranous Nephropathy

Articles related to Membranous Nephropathy:

(showing 4871, show less)
# Title Authors PMID Year
1
Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. 61 56
25394321 2014
2
Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. 61 56
21323541 2011
3
PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. 61 56
21323563 2011
4
Familial membranous nephropathy: an X-linked genetic susceptibility? 61 56
18075275 2008
5
Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. 61 56
12087141 2002
6
Familial membranous nephropathy. 61 56
6439290 1984
7
Membranous glomerulopathy: the evolving story. 54 61
20110811 2010
8
Association between genetic polymorphisms of the NPHS1 gene and membranous glomerulonephritis in the Taiwanese population. 54 61
20138859 2010
9
Antigen identification in membranous nephropathy moves toward targeted monitoring and new therapy. 54 61
20185638 2010
10
Autoimmune kidney diseases. 54 61
19906361 2010
11
Phosphorylation status of nephrin in human membranous nephropathy. 54 61
19882202 2010
12
[The involvement of neprilysin in the pathogenesis of glomerulopathies]. 54 61
19827739 2009
13
Hepatitis B virus associated focal and segmental glomerular sclerosis: report of two cases and review of literature. 54 61
19169768 2009
14
[Immunosuppressive treatment of idiopathic membranous glomerulonephritis with nephrotic syndrome]. 54 61
20088170 2009
15
The transcriptional regulation of podocin (NPHS2) by Lmx1b and a promoter single nucleotide polymorphism. 54 61
19562271 2009
16
Glomerular diseases in a Hispanic population: review of a regional renal biopsy database. 54 61
19820874 2009
17
B cells and tertiary lymphoid organs in renal inflammation. 54 61
18094677 2008
18
[Advances in primary glomerular disease in 2007]. 54 61
18847426 2008
19
Diagnostic value of the aminopeptidase N, N-acetyl-beta-D-glucosaminidase and dipeptidylpeptidase IV in evaluating tubular dysfunction in patients with glomerulopathies. 54 61
18925530 2008
20
Significance of plasma von Willebrand factor level and von Willebrand factor-cleaving protease activity in patients with chronic renal diseases. 54 61
18272039 2008
21
Expression of nestin in the podocytes of normal and diseased human kidneys. 54 61
17255215 2007
22
Alphav beta6 integrin regulates renal fibrosis and inflammation in Alport mouse. 54 61
17200187 2007
23
Role of podocyte slit diaphragm as a filtration barrier. 54 61
16889564 2006
24
Glomerular clusterin is associated with PKC-alpha/beta regulation and good outcome of membranous glomerulonephritis in humans. 54 61
16775601 2006
25
Familial aggregation of primary glomerulonephritis in an Italian population isolate: Valtrompia study. 54 61
16528253 2006
26
Combined top-down and bottom-up mass spectrometric approach to characterization of biomarkers for renal disease. 54 61
16285662 2005
27
Mechanisms of immune-deposit formation and the mediation of immune renal injury. 54 61
16189625 2005
28
Nephrin and podocin dissociate at the onset of proteinuria in experimental membranous nephropathy. 54 61
15882266 2005
29
IgA deficiency and membranous glomerulonephritis presenting as nephrotic syndrome. 54 61
15711951 2005
30
Mouse model of membranous nephropathy induced by cationic bovine serum albumin: antigen dose-response relations and strain differences. 54 61
15385633 2004
31
Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies. 54 61
15464186 2004
32
Glomerular expression of biglycan and decorin and urinary levels of decorin in primary glomerular disease. 54 61
14964452 2004
33
Complement mediates nephrin redistribution and actin dissociation in experimental membranous nephropathy. 54 61
14633129 2003
34
[Pathogenesis of immune glomerulonephritis]. 54 61
15008213 2003
35
Pathological demography of native patients in a nephrology center in China. 54 61
14527370 2003
36
Detection of nuclear factor-kappaB in IgA nephropathy using Southwestern histochemistry. 54 61
12830459 2003
37
Urinary excretion of complement C3d in patients with renal diseases. 54 61
12795640 2003
38
Glomerular expression of connective tissue growth factor mRNA in various renal diseases. 54 61
15012739 2003
39
IgA deficiency with membranous glomerulonephritis: a case report and review. 54 61
12649548 2003
40
Depletion of clusterin in renal diseases causing nephrotic syndrome. 54 61
12427144 2002
41
Differential expression of nephrin in acquired human proteinuric diseases. 54 61
12407641 2002
42
Frequency of renal pathology in Spain 1994-1999. 54 61
12198210 2002
43
Nephrin dissociates from actin, and its expression is reduced in early experimental membranous nephropathy. 54 61
11912254 2002
44
Specific tissue distribution of megsin, a novel serpin, in the glomerulus and its up-regulation in IgA nephropathy. 54 61
11527413 2001
45
Nephrin redistribution on podocytes is a potential mechanism for proteinuria in patients with primary acquired nephrotic syndrome. 54 61
11337370 2001
46
Expression of nephrin in pediatric kidney diseases. 54 61
11158218 2001
47
Clusterin is up-regulated in glomerular mesangial cells in complement-mediated injury. 54 61
11135066 2001
48
No complement receptor 1 stumps on podocytes in human glomerulopathies. 54 61
11135068 2001
49
Vascular hyperpermeability in nephrotic edema. 54 61
10867533 2000
50
Changing incidence of glomerular diseases in adults. 54 61
10793022 2000
51
Expression of megsin mRNA, a novel mesangium-predominant gene, in the renal tissues of various glomerular diseases. 54 61
10589701 1999
52
Expression of the C-C chemokine receptor 5 in human kidney diseases. 54 61
10411679 1999
53
Autoimmune antigen megalin displays similarities with skeletal muscle ryanodine receptor/Ca2+ release channel. 54 61
10341294 1999
54
Glomerular deposition of mannose-binding lectin in human glomerulonephritis. 54 61
10328463 1999
55
Immunogold labelling of cytokines in glomeruli in children with various renal diseases. 54 61
10516492 1999
56
Renal pathology patterns in type II diabetes mellitus: relationship with retinopathy. The Collaborative Study Group. 54 61
9794557 1998
57
Effects of FK506 on experimental membranous glomerulonephritis induced by cationized bovine serum albumin in rats. 54 61
9794552 1998
58
All four putative ligand-binding domains in megalin contain pathogenic epitopes capable of inducing passive Heymann nephritis. 54 61
9727372 1998
59
[An electron microscopic study of circumferential mesangial interposition in various renal diseases]. 54 61
9654910 1998
60
Adhesion molecules and urinary tumor necrosis factor-alpha in idiopathic membranous glomerulonephritis. 54 61
9551397 1998
61
Circulating factors in sera or peripheral blood mononuclear cells in patients with membranous nephropathy or diabetic nephropathy. 54 61
9443093 1997
62
Characterization of proteinuria in primary glomerulonephritides: urinary polymers of albumin. 54 61
9292570 1997
63
The solution structure of the N-terminal domain of alpha2-macroglobulin receptor-associated protein. 54 61
9207124 1997
64
Expression of PDGF and PDGF receptor mRNA in glomeruli in IgA nephropathy. 54 61
9176853 1997
65
The localization of plasminogen activator inhibitor-1 in glomerular subepithelial deposits in membranous nephropathy. 54 61
8959637 1996
66
[A case of Sjögren's syndrome complicated by membranous nephropathy]. 54 61
8913094 1996
67
Increased mRNA expression of metalloproteinase-9 in peripheral blood monocytes from patients with immunoglobulin A nephropathy. 54 61
8712219 1996
68
Cloning and sequencing of human gp330, a Ca(2+)-binding receptor with potential intracellular signaling properties. 54 61
8706697 1996
69
Monocyte chemoattractant protein-1 in normal and diseased human kidneys: an immunohistochemical analysis. 54 61
8556830 1995
70
Urinary excretion of protectin (CD59), complement SC5b-9 and cytokines in membranous glomerulonephritis. 54 61
7543624 1995
71
Effects of posture on creatinine clearance and urinary protein excretion in patients with various renal diseases. 54 61
7634546 1995
72
[Vitronectin in children with renal disease--2. Examination of urinary vitronectin excretion]. 54 61
7541481 1995
73
Elevated plasma levels of acute phase proteins in mesangioproliferative glomerulonephritis, membranous nephropathy and IgA nephropathy. 54 61
7542398 1995
74
Glomerular charge selectivity in primary glomerulopathies. 54 61
7834994 1994
75
A light microscopic study of glomerulosclerosis in Japanese patients with noninsulin-dependent diabetes mellitus: the relationship between clinical and histological features. 54 61
7994933 1994
76
Role of cyclosporine in glomerular diseases. 54 61
7955309 1994
77
An immunohistochemical study of extracellular matrix components and integrins in human glomerular diseases. 54 61
8022108 1994
78
Primary glomerulonephritis with detectable glomerular hepatitis B virus antigens. 54 61
8291656 1994
79
Immunohistochemical studies of vitronectin, C5b-9, and vitronectin receptor in membranous nephropathy. 54 61
7527506 1994
80
Histone-reactive IgA antibodies in adult IgA nephropathy and other primary glomerulonephritis. 54 61
7527503 1994
81
Glomerular disease and urinary Sézary cells in cutaneous T-cell lymphomas. 54 61
8488823 1993
82
[Glomerular permeability for serum proteins in different morphological types of primary chronic glomerulopathy]. 54 61
8378840 1993
83
Role of antibodies to tubulointerstitial nephritis antigen in human anti-tubular basement membrane nephritis associated with membranous nephropathy. 54 61
1466368 1992
84
gp330 associates with a 44-kDa protein in the rat kidney to form the Heymann nephritis antigenic complex. 54 61
1495959 1992
85
Release of arachidonic acid by complement C5b-9 complex in glomerular epithelial cells. 54 61
1909497 1991
86
Localization of 20-kD homologous restriction factor (HRF20) in diseased human glomeruli. An immunofluorescence study. 54 61
1709070 1991
87
Mucosal immunity in primary glomerulonephritis: II. Study of the serum IgA subclass repertoire to food and airborne antigens. 54 61
1766494 1991
88
Isolation of a 330-kDa glycoprotein from human kidney similar to the Heymann nephritis autoantigen (gp330). 54 61
2133428 1990
89
Immunological comparison of patients with rheumatoid arthritis with and without nephropathy. 54 61
2339901 1990
90
Efficacy of leflunomide combined with prednisone for the treatment of PLA2R-associated primary membranous nephropathy. 61
31957527 2020
91
Diagnostic efficacy of serum anti-phospholipase A2 receptor antibodies for idiopathic membranous nephropathy in patients with diabetic kidney disease. 61
31730818 2020
92
Association of diabetes with failure to achieve complete remission of idiopathic membranous nephropathy. 61
31820359 2020
93
Ischemic stroke in anti-phospholipase A2 receptor antibody-positive primary membranous nephropathy: clinical and neuroimaging characteristics. 61
31929373 2020
94
Apolipoprotein E-related glomerular disorders. 61
31874799 2020
95
Membranous nephropathy and cardiovascular events. 61
32037706 2020
96
Membranous nephropathy associated with thrombospondin type-1 domain-containing 7A (THSD7A) in an adult woman with eosinophilia. 61
31705303 2020
97
Renal leukocyte chemotactic factor 2 (ALECT2)-associated amyloidosis in Chinese patients. 61
32024381 2020
98
Resolution of syphilis-related rapidly progressive glomerulonephritis with penicillin therapy: Case report
. 61
31813414 2020
99
The Urinary Angiotensinogen to Urinary Albumin Ratio Reflects Whether the Renin-angiotensin System in the Kidney Is Activated due to Filtration of Plasma Angiotensinogen through the Damaged Glomeruli or the Production of Angiotensinogen in the Proximal Tubules. 61
31534091 2020
100
Triptolide ameliorates fine particulate matter-induced podocytes injury via regulating NF-κB signaling pathway. 61
32013860 2020
101
A case of denosumab-associated membranous nephropathy in a patient with rheumatoid arthritis. 61
31544222 2020
102
Relationship between the status of phospholipase A2 receptor and prognosis of idiopathic membranous nephropathy. 61
31226230 2020
103
Membranous Nephropathy with Rapid Progression. 61
32015602 2020
104
Membranous Nephropathy with Collapse: Poor Prognosis. 61
32015604 2020
105
Membranous nephropathy associated with profound hypothyroidism. 61
31998500 2020
106
Antigens, antibodies, and membranous nephropathy: a decade of progress. 61
31901352 2020
107
Detection of PLA2R Autoantibodies before the Diagnosis of Membranous Nephropathy. 61
31843984 2020
108
Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy. 61
31901340 2020
109
Epitope Mapping of Human α3(IV)NC1-Induced Membranous Nephropathy in Mice. 61
31927545 2020
110
Clinical Relevance of Domain-Specific Phospholipase A2 Receptor 1 Antibody Levels in Patients with Membranous Nephropathy. 61
31843985 2020
111
Refining Our Understanding of the PLA2R-Antibody Response in Primary Membranous Nephropathy: Looking Forward, Looking Back. 61
31871252 2020
112
Differential analysis of urinary albumin for membranous nephropathy patients by online capillary isoelectric focusing - Mass spectrometry. 61
32006679 2020
113
Ofatumumab for multirelapsing membranous nephropathy complicated by rituximab-induced serum-sickness. 61
31980477 2020
114
Association of SNPs in PLA2R1 with idiopathic and secondary membranous nephropathy in two Chinese cohorts. 61
31532353 2020
115
Membranous Nephropathy Due to Anti-GBM Antibodies of Mice and Men. 61
31962308 2020
116
Autoantigens PLA2R and THSD7A in membranous nephropathy share a common epitope motif in the N-terminal domain. 61
31395435 2020
117
Clinical usefulness of anti-M-type phospholipase-A-receptor antibodies in patients with membranous nephropathy and the comparison of three quantification methods. 61
31910103 2020
118
Accelerating the Depletion of Circulating Anti-Phospholipase A2 Receptor Antibodies in Patients with Severe Membranous Nephropathy: Preliminary Findings with Double Filtration Plasmapheresis and Ofatumumab. 61
31336376 2020
119
Clinical value of renal phospholipase A2 receptor deposit in the prognosis evaluation and treatment options of idiopathic membranous nephropathy: A retrospective cohort study. 61
31900967 2020
120
Nephrotic syndrome caused by exposures to skin-lightening cosmetic products containing inorganic mercury. 61
31314603 2020
121
Involvement of prohibitin 1 and prohibitin 2 upregulation in cBSA-induced podocyte cytotoxicity. 61
31883607 2020
122
Characterization of thromboelastography of patients with different pathological types of nephrotic syndrome. 61
32000422 2020
123
Spontaneous Retroperitoneal Hematoma and Membranous Glomerulonephritis; a Case Report. 61
32021983 2020
124
Identification of biomarkers and drug repurposing candidates based on an immune-, inflammation- and membranous glomerulonephritis-associated triplets network for membranous glomerulonephritis. 61
31910852 2020
125
Podocyte autophagy is associated with foot process effacement and proteinuria in patients with minimal change nephrotic syndrome. 61
31978139 2020
126
Patterns in renal diseases diagnosed by kidney biopsy: a single-center experience. 61
31955562 2020
127
Spectrum of biopsy-proven renal disease in northern India: A single-centre study. 61
30834630 2020
128
Tripterygium wilfordii multiglycosides combined with prednisone in the treatment of idiopathic membranous nephropathy: A protocol for a systematic review and meta-analysis. 61
32000425 2020
129
Idiopathic membranous nephropathy preceding membranous lupus nephritis: a case report. 61
31918602 2020
130
Molecular Pathogenesis of Membranous Nephropathy. 61
31622560 2020
131
Membranous nephropathy: diagnosis, treatment, and monitoring in the post-PLA2R era. 61
31811540 2019
132
Management of anticoagulation and antiplatelet therapy in patients with primary membranous nephropathy. 61
31791286 2019
133
Treatment Patterns Among Adults and Children With Membranous Nephropathy in the Cure Glomerulonephropathy Network (CureGN). 61
31844809 2019
134
Treatment of Membranous Nephropathy in Patients With THSD7A Antibodies Using Immunoadsorption. 61
31451329 2019
135
Clinical and pathological features of idiopathic membranous nephropathy with focal segmental sclerosis. 61
31842785 2019
136
Clinicopathological features in membranous nephropathy with cancer: A retrospective single-center study and literature review. 61
31617780 2019
137
Anti-Phospholipase A2 Receptor (Anti-PLA2R) Antibody in Diagnosis and Treatment of Idiopathic Membranous Nephropathy: A Single-Center Observational Study in China. 61
31813930 2019
138
Relationship between renal tissues phospholipase A2 receptor and its serum antibody and clinical condition and prognosis of idiopathic membranous nephropathy: a meta-analysis. 61
31791262 2019
139
Rituximab versus steroids and cyclophosphamide for the treatment of primary membranous nephropathy: protocol of a pilot randomised controlled trial. 61
31806605 2019
140
Immunoadsorption in nephrotic syndrome: Where are we now and where are we going from here? 61
31447217 2019
141
Using Electronic Health Record Data to Rapidly Identify Children with Glomerular Disease for Clinical Research. 61
31732612 2019
142
The anti-PLA2R antibody in membranous nephropathy: what we know and what remains a decade after its discovery. 61
31611068 2019
143
Immune system-mediated cellular and molecular mechanisms in idiopathic membranous nephropathy pathogenesis and possible therapeutic targets. 61
31610191 2019
144
A new mouse model of anti-GBM disease sheds light on maternal transfer of alloantibodies in glomerular disease. 61
31759484 2019
145
The association of acute rejection vs recurrent glomerular disease with graft outcomes after kidney transplantation. 61
31630440 2019
146
Rituximab use in adult glomerulopathies and its rationale. 61
31904761 2019
147
Effect of Low-Density Lipoprotein Apheresis for Nephrotic Idiopathic Membranous Nephropathy as Initial Induction Therapy. 61
30993827 2019
148
Syphilis-Associated Acute Renal Failure and Hepatitis in the Setting of Human Immunodeficiency Virus Coinfection. 61
31764769 2019
149
Effectiveness and safety of cyclophosphamide or tacrolimus therapy for idiopathic membranous nephropathy. 61
31354007 2019
150
N-Acetylglucosamine is the most effective glucosamine derivative for the treatment of membranous nephropathy in rats. 61
31739834 2019
151
Clinical observation on the effect of Wuzhi soft capsule on FK506 concentration in membranous nephropathy patients. 61
31770256 2019
152
Baseline proteinuria level is associated with prognosis in idiopathic membranous nephropathy. 61
31057017 2019
153
MENTOR heralds a new era of therapy for membranous nephropathy. 61
31444480 2019
154
Management of Membranous Nephropathy after MENTOR. 61
31740571 2019
155
Complete remission of membranous nephropathy in a patient with lung adenocarcinoma treated with erlotinib. 61
31730733 2019
156
The role of prophylactic use of low molecular weight heparin or aspirin in thromboembolic events in primary membranous nephropathy. 61
31269849 2019
157
A comparison of clinical features between idiopathic membranous nephropathy patients with and without serum antibody against phospholipase A2 receptor. 61
31702617 2019
158
Comprehensive RNA-Sequencing Analysis in Peripheral Blood Cells Reveals Differential Expression Signatures with Biomarker Potential for Idiopathic Membranous Nephropathy. 61
31566423 2019
159
Lower Serum and Higher Urine Immunoglobulin G Are Associated with an Increased Severity of Idiopathic Membranous Nephropathy. 61
31882429 2019
160
Comprehensive expression profiles and bioinformatics analysis reveal special circular RNA expression and potential predictability in the peripheral blood of humans with idiopathic membranous nephropathy. 61
31545426 2019
161
Proteomics of human glomerulonephritis by laser microdissection and liquid chromatography-tandem mass spectrometry. 61
31707756 2019
162
Renal SGLT mRNA expression in human health and disease: a study in two cohorts. 61
31545924 2019
163
Variations in actual practice patterns and their deviations from the clinical practice guidelines for nephrotic syndrome in Japan: certified nephrologists' questionnaire survey. 61
31385161 2019
164
Primary Membranous Glomerulonephritis: The Role of Serum and Urine Biomarkers in Patient Management. 61
31683874 2019
165
Membranous Glomerulonephritis With Crescents. 61
31890999 2019
166
Anti-glomerular basement membrane disease: an update on subgroups, pathogenesis and therapies. 61
30371823 2019
167
Histological grading in primary membranous nephropathy is essential for clinical management and predicts outcome of patients. 61
31318463 2019
168
Application of miR-193a/WT1/PODXL axis to estimate risk and prognosis of idiopathic membranous nephropathy. 61
31352863 2019
169
Membranous nephropathy caused by rheumatoid arthritis. 61
31037495 2019
170
Pathological spectrum of glomerular disease in patients with renal insufficiency: a single-center study in Northeastern China. 61
31198075 2019
171
Broad spectrum of interferon-related nephropathies-glomerulonephritis, systemic lupus erythematosus-like syndrome and thrombotic microangiopathy: A case report and review of literature. 61
31750091 2019
172
A case of membranous nephropathy diagnosed with lupus nephritis 11 years after onset. 61
31399881 2019
173
Tuberculosis as a microbiologically proven etiology of membranous nephropathy and interstitial nephritis. 61
31929294 2019
174
A novel mouse model of phospholipase A2 receptor 1-associated membranous nephropathy mimics podocyte injury in patients. 61
32033781 2019
175
Design and validation of a scoring model for differential diagnosis of diabetic nephropathy and nondiabetic renal diseases in type 2 diabetic patients. 61
31602779 2019
176
Soluble Urokinase Receptor Levels in Secondary Focal Segmental Glomerulosclerosis. 61
31768381 2019
177
Clinicopathological analysis of IgA nephropathy combined with other glomerular diseases. 61
31593089 2019
178
Proteomics and Metabolomics in Kidney Disease, including Insights into Etiology, Treatment, and Prevention. 61
31636087 2019
179
Rituximab or Cyclosporine for Membranous Nephropathy. 61
31644855 2019
180
Rituximab or Cyclosporine for Membranous Nephropathy. 61
31644856 2019
181
Rituximab or Cyclosporine for Membranous Nephropathy. Reply. 61
31644857 2019
182
More about Factor H Autoantibodies in Membranous Nephropathy. 61
31618548 2019
183
Membranous Nephropathy Posttransplantation: An Update of the Pathophysiology and Management. 61
31568231 2019
184
Acute Kidney Injury Following Exposure to Calcineurin Inhibitors in a Patient with Idiopathic Membranous Nephropathy. 61
31587119 2019
185
Serum uric acid is an independent predictor of renal outcomes in patients with idiopathic membranous nephropathy. 61
31463703 2019
186
Treatment of idiopathic membranous nephropathy in adults: KDIGO 2012, cyclophosphamide and cyclosporine A are out, rituximab is the new normal. 61
31583088 2019
187
Transplantation of Mouse Induced Pluripotent Stem Cell-Derived Podocytes in a Mouse Model of Membranous Nephropathy Attenuates Proteinuria. 61
31664077 2019
188
Features of phospholipase A2 receptor and thrombospondin type-1 domain-containing 7A in malignancy-associated membranous nephropathy. 61
31243053 2019
189
Predicting risk of pulmonary infection in patients with primary membranous nephropathy on immunosuppressive therapy: The AIM-7C score. 61
30499223 2019
190
Efficacy and safety of tacrolimus-based treatment for nephrotic idiopathic membranous nephropathy in young adults: A retrospective study. 61
31225949 2019
191
Comparative analysis of membranous and other nephropathy subtypes and establishment of a diagnostic model. 61
30097959 2019
192
A rare case of PLA2R- and THSD7A-positive idiopathic membranous nephropathy. 61
31663595 2019
193
Concurrent mucous membrane pemphigoid and membranous glomerulonephritis in a patient with autoantibodies targeting the 1080 region of collagen XVII. 61
30916378 2019
194
Glomerular Immunodeposits of Patients with IgA Nephropathy Are Enriched for IgG Autoantibodies Specific for Galactose-Deficient IgA1. 61
31444275 2019
195
Co-occurrence of PLA2R-positive membranous nephropathy without crescents, and PR3-positive eosinophilic granulomatosis with polyangiitis
. 61
31347497 2019
196
Patients with Idiopathic Membranous Nephropathy: A Real-World Clinical and Economic Analysis of U.S. Claims Data. 61
31283419 2019
197
Membranous nephropathy in a child with crescentic glomerulonephritis: Coincidence or comorbidity? 61
31696856 2019
198
Clinical outcomes and effects of treatment in older patients with idiopathic membranous nephropathy. 61
31408925 2019
199
Prognostic value of phospholipase A2 receptor in primary membranous nephropathy: a systematic review and meta-analysis. 61
31140029 2019
200
Diagnostic role of renal biopsy in PLA2R1-antibody-positive patients with nephrotic syndrome. 61
30962506 2019
201
Interaction between PLA2R1 and HLA-DQA1 variants contributes to the increased genetic susceptibility to membranous nephropathy in Western China. 61
30467913 2019
202
Membranous nephropathy and thrombotic microangiopathy secondary to metastatic prostate cancer after Iodine-125 prostate brachytherapy: A case report
. 61
31262399 2019
203
The immunohistological profile of membranous nephropathy associated with chronic Schistosoma mansoni infection reveals a glomerulopathy with primary features. 61
31445585 2019
204
Comparative efficacy of 13 immunosuppressive agents for idiopathic membranous nephropathy in adults with nephrotic syndrome: a systematic review and network meta-analysis. 61
31511292 2019
205
Serum anti-phospholipase A2 receptor (PLA2R) antibody detected at diagnosis as a predictor for clinical remission in patients with primary membranous nephropathy: a meta-analysis. 61
31533641 2019
206
Mycophenolate mofetil and tacrolimus versus tacrolimus alone for the treatment of idiopathic membranous glomerulonephritis: a randomised controlled trial. 61
31492152 2019
207
Urinary levels of podocyte-derived microparticles are associated with the progression of chronic kidney disease. 61
31700881 2019
208
Nephrotic syndrome: immunological mechanisms. 61
31630708 2019
209
Crystal structure of the CTLD7 domain of human M-type phospholipase A2 receptor. 61
31271865 2019
210
Syphilis and parvovirus B19 co-infection imitating a lupus nephropathy: A case report. 61
31490394 2019
211
Membranous Lupus Nephritis: A Clinical Review. 61
31733724 2019
212
Pattern of biopsy-proven kidney diseases: experience of a teaching hospital in Bahawalpur, Pakistan. 61
31696854 2019
213
Diabetic Nephropathy versus Diabetic Retinopathy in a Chinese Population: A Retrospective Study. 61
31455757 2019
214
Urinary miRNA-27b-3p and miRNA-1228-3p correlate with the progression of Kidney Fibrosis in Diabetic Nephropathy. 61
31388051 2019
215
Rituximab bioavailability in primary membranous nephropathy. 61
30929012 2019
216
High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy. 61
31340979 2019
217
Does Epitope Spreading Influence Responsiveness to Rituximab in PLA2R-Associated Membranous Nephropathy? 61
31340980 2019
218
Complement activation products in the circulation and urine of primary membranous nephropathy. 61
31399080 2019
219
Recurrent venous thromboembolism in primary membranous nephropathy despite direct Xa inhibitor therapy. 61
30421320 2019
220
Reversal of endothelial dysfunction post-immunosuppressive therapy in adult-onset podocytopathy and primary membranous nephropathy. 61
32004823 2019
221
Effectiveness and Safety of Cyclophosphamide or Tacrolimus Therapy for Idiopathic Membranous Nephropathy. 61